The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Efficacy, Safety, and Tolerability of Once-Daily Niacin for the Treatment of Dyslipidemia Associated With Type 2 Diabetes<subtitle>Results of the Assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial</subtitle>
Abstract
BACKGROUND: Diabetic dyslipidemia is characterized by high triglyceride levels; low high-density lipoprotein cholesterol levels; small, dense low-density lipoprotein particles; and high free fatty acid levels. Niacin reduces concentrations of triglyceride-rich and small low-density lipoprotein particles while increasing high-density lipoprotein cholesterol levels. It also lowers levels of free fatty acids and lipoprotein(a). However, the use of niacin in patients with diabetes has been discouraged because high doses can worsen glycemic control. We evaluated the efficacy and safety of once-daily extended-release (ER) niacin in patients with diabetic dyslipidemia. METHODS: During a 16-week, double-blind, placebo-controlled trial, 148 patients were randomized to placebo (n = 49) or 1000 (n = 45) or 1500 mg/d (n = 52) of ER niacin. Sixty-nine patients (47%) were also receiving concomitant therapy with statins. RESULTS: Dose-dependent increases in high-density lipoprotein cholesterol levels (+19% to +24% [P<.05] vs placebo for both niacin dosages) and reductions in triglyceride levels (-13% to -28% [P<.05] vs placebo for the 1500-mg ER niacin) were observed. Baseline and week 16 values for glycosylated hemoglobin levels were 7.13% and 7.11%, respectively, in the placebo group; 7.28% and 7.35%, respectively, in the 1000-mg ER niacin group (P=.16 vs placebo); and 7.2% and 7.5%, respectively, in the 1500-mg ER niacin group (P=.048 vs placebo). Four patients discontinued participation because of inadequate glucose control. Rates of adverse event rates other than flushing were similar for the niacin and placebo groups. Four patients discontinued participation owing to flushing (including 1 receiving placebo). No hepatotoxic effects or myopathy were observed. CONCLUSION: Low doses of ER niacin (1000 or 1500 mg/d) are a treatment option for dyslipidemia in patients with type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lower doses of nicotinic acid lessen this risk.”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [169]
In the citing paper
“It can significantly increase blood glucose at high doses, but recent studies demonstrate that at modest doses (750–2,000 mg/day), significant improvements in LDL cholesterol, HDL cholesterol, and triglyceride levels are accompanied by only modest changes in glucose that are generally amenable to adjustment of diabetes therapy (205,206).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [206]
Citations
Cites
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Grundy, S. M., Benjamin, I. J., Burke, G. L., Chait, A., Eckel, R. H., Howard, B. V., Mitch, W., Smith, S. C., & Sowers, J. R. (1999) · Circulation · doi:10.1161/01.cir.100.10.1134 · Cited by 2,698
Self-citationClofibrate and Niacin in Coronary Heart Disease
Stamler, J. (1975) · JAMA · doi:10.1001/jama.1975.03240160024021 · Cited by 1,750
Pyörälä, K., Pedersen, T. R., Kjekshus, J., Faergeman, O., Olsson, A. G., Thorgeirsson, G., & The Scandinavian Simvastatin Survival Study (4S) Group (1997) · Diabetes Care · doi:10.2337/diacare.20.4.614 · Cited by 1,623 · cited 1×
“60 Missing 0 1 (2) 0 Added new drug/increased dose‡ 8 (16) 11 (24) 15 (29) .”
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
Robins, S. J., Collins, D. E., Wittes, J. T., Papademetriou, V., DEEDWANIA, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., WEXLER, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 917
Diabetes and atherosclerosis: An epidemiologic view
Pyörälà, K., Laakso, M., & Uusitupa, M. I. J. (1987) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610030206 · Cited by 912
Królewski, A. S., Kosinski, E. J., Warram, J. H., Leland, O. S., Busick, E. J., Asmal, A. C., Rand, L. I., Christlieb, A. R., Bradley, R. F., & Kahn, C. R. (1987) · The American Journal of Cardiology · doi:10.1016/0002-9149(87)91086-1 · Cited by 654
Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart Study
Koskinen, P., Mänttäri, M., Manninen, V., Huttunen, J. K., Heinonen, O. P., & Frick, M. H. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.820 · Cited by 509
Elam, M. B., Hunninghake, D. B., Davis, K. B., Garg, R., Johnson, C. W., Egan, D., Kostis, J. B., Sheps, D. S., Brinton, E. A., & for the ASTEROID Investigators (2000) · JAMA · doi:10.1001/jama.284.10.1263 · Cited by 509
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 549
Mitochondrial Function in Diabetes
Mechanick, J. I. (2006) · Nutrition and disease prevention · doi:10.1201/9781420014884.ch13 · Cited by 3
Murray, M. T. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4377-2333-5.00161-9 · Cited by 3
Combination Therapy for Dyslipidemia
Davidson, D., Wilkinson, M. J., & Davidson, M. H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00027-x · Cited by 3
Niacin: Risk Benefits and Role in Treating Dyslipidemias
Guyton, J. R., Campbell, K. B., & Lakey, W. C. (2015) · Contemporary Endocrinology · doi:10.1007/978-1-60761-424-1_26 · Cited by 3
Nilsson, P., Viljoen, A., & Wierzbicki, A. (2010) · doi:10.1002/9781444324808.ch40 · Cited by 1
Management of dyslipidemias in the age of statins
Green, M. L. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00095-2 · Cited by 3
Resurrecting an old drug - a flash in the pan or here to stay?
Viljoen, A. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01967.x · Cited by 3
Cholesteryl ester transfer protein inhibition and the treatment of metabolic syndrome
Clark, R. W., & Brousseau, M. E. (2005) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2005.05.004 · Cited by 3
Al-Shaer, M. H., & Jerome, W. P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.006 · Cited by 3
Treatment of lipids and type 2 diabetes
Hermayer, K. (2004) · Current Cardiology Reports · doi:10.1007/s11886-004-0053-4 · Cited by 4
Achieving the therapeutic benefits of Niaspan® in daily practice
Reasner, C. (2006) · European Heart Journal Supplements · doi:10.1093/eurheartj/sul044 · Cited by 3
Optimizing nicotinic acid delivery for durable antilipolysis and improved metabolic control
Kroon, T. (2016) · Epsilon Open Archive (Sveriges lantbruksuniversitet biblioteket (Swedish University of Agricultural Sciences)) · Cited by 3
Combination therapy with statins
Thompson, G. R. (2003) · CRC Press eBooks · doi:10.1201/b14304-14 · Cited by 3
Standards of Medical Care in Diabetes
American Diabetes Association (2005) · Diabetes Care · doi:10.2337/diacare.28.suppl_1.s4 · Cited by 2
Assessment and Modification of Cardiovascular Disease Risk in the HIV-Infected Individual
Ross, A. C., & McComsey, G. A. (2011) · Future Virology · doi:10.2217/fvl.11.8 · Cited by 2
Haynes, R., & Rahimi, K. (2016) · Heart · doi:10.1136/heartjnl-2015-308558 · Cited by 2
Lamb, J. J., Konda, V. R., Desai, A., Bland, J. S., & Tripp, M. L. (2012) · Global Advances in Health and Medicine · doi:10.7453/gahmj.2012.1.4.012 · Cited by 2
Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2011) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2011.07.003 · Cited by 2
Cholesterol Management in Patients with Chronic Kidney Disease
Toto, R. D., Vega, G. L., & Grundy, S. M. (2008) · Elsevier eBooks · doi:10.1016/b978-141605484-9.50065-4 · Cited by 2
Self-citationGouni‐Berthold, I., Betteridge, D., & Krone, W. (2007) · CRC Press eBooks · doi:10.3109/9780849379581-28 · Cited by 2
Hyperglycemia Secondary to Nondiabetic Conditions and Therapies
Lebovitz, H. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00043-5 · Cited by 2
Diabetes Mellitus Types I and II
Murray, M. T. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-43044-9.00165-5 · Cited by 2
Updated management of dyslipidaemia in diabetes: A new step towards more stringent targets
Monnier, L., Schlienger, J.-L., & Colette, C. (2021) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2021.100001 · Cited by 2
Goldberg, R. B. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.006 · Cited by 2
Hansel, B., Bastard, J., & Bruckert, É. (2011) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(11)51209-0 · Cited by 2
Diabetic dyslipidaemia: the triad
Wierzbicki, A. S. (2006) · European Heart Journal Supplements · doi:10.1093/eurheartj/sul038 · Cited by 2
Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?
Steiner, G. A. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283189c2b · Cited by 2
Mukherjee, S., & Rees, J. A. (2006) · Practical Diabetes · doi:10.1002/pdi.916 · Cited by 2
Toxicity of antilipidemic agents: Facts and fictions
Xydakis, A. M., & Jones, P. H. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0012-3 · Cited by 2
The Use of Niacin in Diabetes Mellitus
Mikhail, N. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.3.369-a · Cited by 2
Rational therapy of mixed dyslipidaemia in a patient with diabetes
Reasner, C. A. (2007) · The British Journal of Diabetes · doi:10.1177/14746514070070010501 · Cited by 2
Jones, P. H. (2006) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2006.04752.x · Cited by 2
Pharmacological Therapy for Cardiovascular Disease
Davidson, M. H. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-533-6_7 · Cited by 2
Cheang, K. I. (2006) · The Consultant Pharmacist · doi:10.4140/tcp.n.2006.493 · Cited by 2
Utilization Pattern of Statins in an Indian Population.
Raj, N. (2012) · Cited by 2
Niacin for primary and secondary prevention of cardiovascular events
Saccilotto, R. T., Kasenda, B., Nordmann, A. J., & Briel, M. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009744 · Cited by 2
Diabetic peripheral vascular disease
Tripathi, R. K., & Vaddavalli, V. V. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95469-3.00026-7 · Cited by 2
Monnier, L., Schlienger, J.-L., & Colette, C. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.02.015 · Cited by 1
Fruchart, J., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Češka, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2010) · Cor et Vasa · doi:10.33678/cor.2010.056 · Cited by 1
Bhargava, A., Gleason, S., Vaughan, A. G., Johnson, J. F., & Yarlagadda, K. V. S. N. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12199 · Cited by 1
Are add-on agents to statin therapy necessary in hypercholesterolemia?
Dayer-Berenson, L., Finckenor, M., & Tuzzolino, M. (2014) · Clinical Lipidology · doi:10.2217/clp.14.57 · Cited by 1
Risikoadaptierte Therapie von Gefäßerkrankungen—
Fischer, S. (2005) · Zeitschrift für Kardiologie · doi:10.1007/s00392-005-1407-7 · Cited by 1
Kaore, S. N., Yadav, V. K., & Kaore, N. M. (2013) · International Journal of Pharma and Bio Sciences · Cited by 1
Welty, F. K. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-1366-4.00015-9 · Cited by 1
Special Patient Populations: Diabetes and Metabolic Syndrome
Kurra, S., Chahil, T. J., & Ginsberg, H. N. (2009) · Elsevier eBooks · doi:10.1016/b978-141605469-6.50041-x · Cited by 1
Sawhney, A. G., & Rothkopf, M. M. (2014) · CRC Press eBooks · doi:10.1201/b17616-7 · Cited by 2
Klose, G., & Schwabe, U. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_31 · Cited by 1
Yilmaz, B. A., & Törüner, F. B. (2013) · CRC Press eBooks · doi:10.1201/b14907-9 · Cited by 1
Zięba, K., Płonka, M., Wróbel, A., Klupa, T., & Matejko, B. (2022) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2022-0040 · Cited by 1
Strategies for Treating Abnormal Lipid Profiles with Drugs
Stone, N. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_8 · Cited by 1
Drug Treatment in the Metabolic Syndrome
Karathanasis, S. K., & SCHIEBINGER, R. J. (2005) · Elsevier eBooks · doi:10.1016/b978-84-8174-892-5.50027-9 · Cited by 1
Mancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.07.015 · Cited by 1
Hyperglycemia Secondary to Nondiabetic Conditions and Therapies
Lebovitz, H. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00042-1 · Cited by 1
Niacin supplementation impairs exercise performance
Davis, G. R., & Nelson, A. G. (2021) · International Journal for Vitamin and Nutrition Research · doi:10.1024/0300-9831/a000736 · Cited by 1
Al-Shaer, M. H., & AbuSabha, H. S. (2004) · Lipids in Health and Disease · doi:10.1186/1476-511x-3-23 · Cited by 1
Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL
Ascaso, J. F., Santos, P. G., Mijares, A. H., Rojas, A. M., Marín, L. M., Núñez-Cortés, J. M., Pallardo, L. F., Pedro‐Botet, J., Jiménez, F. P., Pintó, X., et al. (2007) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(07)74207-9 · Cited by 1
The role of lipid management in diabetes
Ganda, O. P. (2005) · Cardiology Clinics · doi:10.1016/j.ccl.2004.06.002 · Cited by 1
Lipid Regulation with Niacin Extended-Release (Niaspan-R™)
Vosper, H. (2011) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s5155 · Cited by 1
Vega, G., Vajja, M., Palacio, N., Caterp, N. B., & Grundy, S. (2006) · Current Therapeutic Research · doi:10.1016/j.curtheres.2006.10.002 · Cited by 1
Self-citationBarter, P. J. (2005) · The British Journal of Diabetes · doi:10.1177/1474651405005002s0101 · Cited by 1
Wild, S. H., & Byrne, C. D. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050060301 · Cited by 1
High-density lipoprotein cholesterol: ready for prime time?
Yc, K. (2005) · PubMed · Cited by 1
C-Reactive Protein as a Marker for Cardiovascular Disease
Backes, J. M., & Howard, P. A. (2004) · Hospital Pharmacy · doi:10.1177/001857870403900804 · Cited by 1
Niacin?ein komplement�rer Therapieansatz zur Optimierung des Lipidprofils
Wieneke, H., Schmermund, A., & Erbel, R. (2005) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-005-1020-6 · Cited by 1
Should We Treat the Metabolic Syndrome or Its Components?
(2007) · Humana Press eBooks · doi:10.1007/978-1-59745-431-5_10 · Cited by 1
Klose, G., & Schwabe, U. (2010) · Springer eBooks · doi:10.1007/978-3-642-13380-0_31 · Cited by 1
OTHER ARTICLES NOTED (Nov 01 to 18 Oct 02)
(2003) · Evidence-Based Nursing · doi:10.1136/ebn.6.1.e1 · Cited by 1
Viljoen, A., Handhle, A., & Wierzbicki, A. S. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch48 · Cited by 1
Cholesterol lowering in diabetes
Rosenson, R. S. (2005) · Postgraduate Medicine · doi:10.3810/pgm.2005.04.1607
Nouvel, J. (2005) · AV: Monografías
Metabolic Regulation of Endothelial Dysfunction and Cardiovascular Risk
Young, J. M. (2012) · Otago University Research Archive (University of Otago)
Patients with low levels of high-density lipoprotein cholesterol: to treat or not to treat?
Tavintharan, S., Lim, S. C., & Sum, C. F. (2005) · PubMed · Cited by 7
Lipoproteins in Diabetes: Risk and Opportunity
Guyton, J. R. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_17
Mechanism of Action of Niacin: Implications for Atherosclerosis and Drug Discovery
Marar, D., Ganji, S. H., Kamanna, V. S., & Kashyap, M. L. (2011) · doi:10.1002/9780470910016.ch9
Does Treating Hyperlipidaemia with Medication Prevent Complications?
Colhoun, H. M. (2010) · Wiley eBooks · doi:10.1002/9780470682807.ch13
Hypolipidemic Agents and Their Role in the Therapy of Diabetes Mellitus
Taskinen, M. (2004) · Wiley eBooks · doi:10.1002/0470862092.d0615
Pharmacologic Factors Affecting Glycemic Control
Lien, L. F., & Lane, J. D. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-043-4_29
Individualized Tailoring of Hypolipidemic Pharmacological Treatment
Tzeis, S. E., Pyrros, I., Andrikopoulos, G. K., Kappos, K. G., & Manolis, A. S. (2006) · Hospital chronicles/Hospital Chronicles
Chaveles, I. (2010) · Hospital chronicles/Hospital Chronicles
Telmisartan and enalapril in type 2 diabetes
Barnett, A. H. (2005) · The British Journal of Diabetes · doi:10.1177/14746514050050010501
Small Dense Low-density Lipoprotein and Cardiovascular Disease
Suh, S., & Lee, M. (2012) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2012.1.1.1
Recent publications of interest in other journals
Faria, S. H., & Flannery, J. C. (2004) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2004.08.001
Diabetic dyslipidaemia: the role of niacin derivatives lack long-term outcome data
Varughese, G. I., & Scarpello, J. H. B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01142.x
L’acide nicotinique dans le traitement des dyslipidémies
Fredenrich, A. (2008) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(08)70006-3
High-Sensitivity C-Reactive Protein and Cardiovascular Disease
Mohsin, M., & Ahmed, M. S. (1970) · Cardiovascular Journal · doi:10.3329/cardio.v3i2.9188
Reducing Cardiovascular Risk and Managing Dyslipidemia in Women
Appel, S. J., Floyd, N. A., & Jones, E. J. (2007) · Nursing for Women s Health · doi:10.1111/j.1751-486x.2007.00245.x
Tratamiento farmacológico de la dislipemia en la diabetes mellitus tipo 2
Real, J. T., & Carmena, R. (2008) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(08)76267-3
Prolonged‐release nicotinic acid
Ho, C. K. M., Strachan, M., & Walker, S. (2009) · Practical Diabetes · doi:10.1002/pdi.1362
Sophisticated Tests for Susceptibility to Atherosclerosis:An Added Value for Heart Hospitals
Superko, H. R. (2003) · The American Heart Hospital Journal · doi:10.1111/j.1541-9215.2003.02362.x
Smith, C. S., Spertus, J. A., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Grundy, S. M., Cleeman, J. I., Daniels, S. R., & Donato, K. A. (2006)
Self-citationClinical Utility of extended-release Niacin: Update and Summary
Cheung, R. J., & Ito, M. K. (2005) · Future Cardiology · doi:10.2217/14796678.1.5.571
Dyslipidemia treatment: current considerations and unmet needs
Malik, S., & Kashyap, M. L. (2003) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.1.121
Raising high-density lipoprotein
Wierzbicki, A. S. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2004.00333.x
Pharmacological treatment of lipid disorders in diabetes
Brown, W. V. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2004.00321.x
Shuster, J. E., Jeffres, M. N., Barclay, S. M., & Bhakta, R. (2011) · Dialnet (Universidad de la Rioja)
Cardiovascular Medications: Pharmacokinetics and Pharmacodynamics
Raza, J. A., Kreeger, R. W., & Movahed, A. (2008) · Springer eBooks · doi:10.1007/978-3-540-78674-0_37
Mesquita, E. T., Junior, C. V. S., de Suplemento, Guimarães, J. I., Liberman, B., Mansur, A. J., Sousa, A. G. M. R., Sposito, A. C., Rassi, A., Lopes, A. A., et al. (2005)
Millán, J., Pedro‐Botet, J., Pintó, X., & Espa, S. (2012)
Metadata
- Authors
- Grundy, S. M.
- Affiliations
- The University of Texas at Austin (US)
- Corresponding author
- Grundy, Scott M.
- ORCID
- Grundy, Scott M.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2002-07-22
- Volume
- 162
- Issue
- 14
- Pages
- 1568
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2119065130
- Cited by
- 551
- References
- 21
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 8 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 6 · 2015: 16 · 2014: 14 · 2013: 31 · 2012: 28
- FWCI
- 50.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- nicotinic acid, extended-release niacin, diabetic dyslipidemia, type 2 diabetes, hypertriglyceridemia, HDL cholesterol, triglycerides, glycemic control, statin combination therapy, lipoprotein(a), drug safety and tolerability, dose-response relationship, hepatotoxicity, myopathy, HbA1c, small dense LDL
- MeSH terms
- Adult, Aged, Hypolipidemic Agents, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Follow-Up Studies, Humans, Hyperlipidemias, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Niacin, Triglycerides, United States, Biomarkers, Body Mass Index, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
